open access

Vol 10, No 3 (2017)
Poglądy, stanowiska, zalecenia, standardy i opinie
Get Citation

Rules preventing the transfer of malignant tumor from organ donor to the recipient. Determination of tumor markers in donor evaluation Polish Transplant Society Working Group Position (PTS WG) Second edition updated

Alicja Dębska-Ślizień1, Jarosław Czerwiński2, Leszek Domański3, Maciej Kosieradzki4, Dariusz Patrzałek5, Krystyna Serkies6
Forum Nefrologiczne 2017;10(3):198-224.
Affiliations
  1. Katedra i Klinika Nefrologii, Transplantologii i Chorób Wewnętrznych, Gdański Uniwersytet Medyczny, Dębinki 7, 80–211 Gdańsk, Poland
  2. Centrum Organizacyjno-Koordynacyjne ds. Transplantacji „Poltransplant”
  3. Klinika Nefrologii, Transplantologii i Chorób Wewnętrznych, Pomorski Uniwersytet Medyczny
  4. Katedra i Klinika Chirurgii Ogólnej i Transplantacyjnej, Warszawski Uniwersytet Medyczny
  5. 4. Wojskowy Szpital Kliniczny z Polikliniką, Wrocław
  6. Klinika Onkologii i Radioterapii, Gdański Uniwersytet Medyczny

open access

Vol 10, No 3 (2017)
Poglądy, stanowiska, zalecenia, standardy i opinie

Abstract

Transmission of cancer from donor to organ recipient is very rare (2.2/10 000 transplants — ONT Registry, Spain; 1.3/10 000 transplants — UNOS Registry, USA), but carries serious consequences. It is therefore mandatory to evaluate the donor for the presence of cancer at the time of potential donor evaluation or in the past in order to reduce the risk of transmission of cancer cells with transplanted organ. Following general recommendations largely avoids the transfer of cancer, however each potential donor, especially elder donor requires careful evaluation in this regard. The risk of transmission depends on the type of the cancer (histological type of the tumor and its histological grading) and clinical stage (staging).

For some cancers like basal cell carcinoma (BCC) and squamous skin (SCC) organ metastasis risk is negligible, hence organs from such donors may be accepted for transplantation. For other tumors, including brain tumors donor acceptance depends not only on the type of the tumor and its severity (staging/grading) but also from the policy of transplant center and the clinical situation of the recipient. In Europe there are no uniform recommendations for
the acceptance of donors diagnosed with cancer before and during organ procurement. Below is a brief outline recommendations of European Directorate for the Quality of Medicines & Health Care (EDQM), Council of Europe from 2016 and the position of the Polish Transplant Society Working Group (PTS WG) on this issue. In addition we present the position of PTS WG on determination of tumor markers in potential organ donors based on above recommendations, Poltransplant Recommendation 2009, and the strategy of Italian National Transplant Registry Centre (CNT).

Abstract

Transmission of cancer from donor to organ recipient is very rare (2.2/10 000 transplants — ONT Registry, Spain; 1.3/10 000 transplants — UNOS Registry, USA), but carries serious consequences. It is therefore mandatory to evaluate the donor for the presence of cancer at the time of potential donor evaluation or in the past in order to reduce the risk of transmission of cancer cells with transplanted organ. Following general recommendations largely avoids the transfer of cancer, however each potential donor, especially elder donor requires careful evaluation in this regard. The risk of transmission depends on the type of the cancer (histological type of the tumor and its histological grading) and clinical stage (staging).

For some cancers like basal cell carcinoma (BCC) and squamous skin (SCC) organ metastasis risk is negligible, hence organs from such donors may be accepted for transplantation. For other tumors, including brain tumors donor acceptance depends not only on the type of the tumor and its severity (staging/grading) but also from the policy of transplant center and the clinical situation of the recipient. In Europe there are no uniform recommendations for
the acceptance of donors diagnosed with cancer before and during organ procurement. Below is a brief outline recommendations of European Directorate for the Quality of Medicines & Health Care (EDQM), Council of Europe from 2016 and the position of the Polish Transplant Society Working Group (PTS WG) on this issue. In addition we present the position of PTS WG on determination of tumor markers in potential organ donors based on above recommendations, Poltransplant Recommendation 2009, and the strategy of Italian National Transplant Registry Centre (CNT).

Get Citation

Keywords

transplantation; donor with cancer; risk of cancer transmission

About this article
Title

Rules preventing the transfer of malignant tumor from organ donor to the recipient. Determination of tumor markers in donor evaluation Polish Transplant Society Working Group Position (PTS WG) Second edition updated

Journal

Renal Disease and Transplantation Forum

Issue

Vol 10, No 3 (2017)

Pages

198-224

Bibliographic record

Forum Nefrologiczne 2017;10(3):198-224.

Keywords

transplantation
donor with cancer
risk of cancer transmission

Authors

Alicja Dębska-Ślizień
Jarosław Czerwiński
Leszek Domański
Maciej Kosieradzki
Dariusz Patrzałek
Krystyna Serkies

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.